Design and Synthesis of Novel 2‐Acetamido, 6‐Carboxamide Substituted Benzothiazoles as Potential BRAFV600E Inhibitors – In vitro Evaluation of their Antiproliferative Activity
Open Access
- 24 October 2023
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 18 (22) , e202300322
Abstract
The oncogenic BRAFV600E kinase leads to abnormal activation of the MAPK signaling pathway and thus, uncontrolled cellular proliferation and cancer development. Based on our previous virtual screening studies which issued 2‐acetamido‐1,3 benzothiazole‐6‐carboxamide scaffold as active pharmacophore displaying selectivity against the mutated BRAF, eleven new substituted benzothiazole derivatives were designed and synthesized by coupling of 2‐acetamidobenzo[d]thiazole‐6‐carboxylic acid with the appropriate amines in an effort to provide even more efficient inhibitors and tackle drug resistance often developed during cancer treatment. All derived compounds bore the benzothiazole scaffold substituted at position‐2 by an acetamido moiety and at position‐6 by a carboxamide functionality, the NH moiety of which was further linked through an alkylene linker to a sulfonamido (or amino) aryl (or alkyl) functionality or a phenylene linker to a sulfonamido aromatic (or non‐aromatic) terminal pharmacophore in the order −C6H4−NHSO2−R or reversely −C6H4−SO2N(H)−R. These analogs were subsequently biologically evaluated as potential BRAFV600E inhibitors and antiproliferative agents in several colorectal cancer and melanoma cell lines. In all assays applied, one analog, namely 2‐acetamido‐N‐[3‐(pyridin‐2‐ylamino)propyl]benzo[d]thiazole‐6‐carboxamide (22), provided promising results in view of its use in drug development.Keywords
Funding Information
- European Commission (MIS-5000432)
- European Commission
This publication has 42 references indexed in Scilit:
- BRAF as a therapeutic target: a patent review (2006 – 2012)Expert Opinion on Therapeutic Patents, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA ResistancePLOS ONE, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamideBioorganic & Medicinal Chemistry, 2009
- BH3-only proteins in apoptosis and beyond: an overviewOncogene, 2008
- Highly specific N-monomethylation of primary aromatic aminesTetrahedron, 2006
- Discovery of a Novel Non-Peptide Somatostatin Agonist with SST4 SelectivityJournal of the American Chemical Society, 1998